Dellon ES, et al. - In a double-blind, double-dummy trial, researchers ascertained if oral viscous budesonide (OVB) was more effective than multi-dose inhaler (MDI) for initial treatment of patients with eosinophilic esophagitis (EoE). Patients with a new EoE diagnosis were randomly assigned to groups of either OVB (1mg/4mL) twice daily plus placebo inhaler (n=56) or MDI fluticasone (880 mcg) twice daily plus placebo slurry (n=55) for 8 weeks. Investigators observed that EoE initial treatment with either OVB or fluticasone MDI resulted in a significant reduction in esophageal eosinophil counts and improved dysphagia and endoscopic characteristics. OVB was not superior to MDI, however, so either treatment for EoE is acceptable.